DACH1: A Potential Drug Target and Biomarker (G1602)

Target Name: DACH1

NCBI ID: G1602

DACH1

DACH1: A Potential Drug Target and Biomarker

Drug resistance is a major issue in modern medicine, and the development of new treatments is crucial to combat this issue. One potential solution to this problem is the identification of drug targets, which are molecules that are affected by a drug and can be targeted to inhibit their function. One promising lead in this field is the DACH1 gene, which has been identified as a potential drug target and biomarker.

The DACH1 gene

The DACH1 gene is a member of the TATA-binding protein (TBP) gene family, which is a group of non-coding DNA elements that play a critical role in the regulation of gene expression. The DACH1 gene is located on chromosome 19 and encodes a protein known as DAC homolog (DAC-like).

The DAC-like protein functions as a negative regulator of gene expression, which means that when it is bound to a specific DNA sequence, it prevents the growth of the gene that is nearby. This function is critical for the regulation of cell growth, development, and survival, and is implicated in a wide range of biological processes, including cancer, neurodegenerative diseases, and developmental disorders.

DAC-like protein function

The DAC-like protein functions as a negative regulator of gene expression by binding to specific DNA sequences and preventing their growth. This function is critical for the regulation of cell growth and development, and is implicated in a wide range of biological processes, including cancer, neurodegenerative diseases, and developmental disorders.

One of the key functions of the DAC-like protein is its ability to interact with the transcription factor p53, which is a key regulator of gene expression in cells. The DAC-like protein has been shown to physically interact with p53 and prevent its from activating target genes. This interaction between the DAC-like protein and p53 is critical for the regulation of cell growth and development, and is a potential drug target.

DAC-like protein dysfunction

DAC-like protein dysfunction is a leading cause of drug resistance in cancer. The DAC-like protein is widely expressed in many types of cancer, including breast, lung, and ovarian cancer. It is also a potent drug target, and has been shown to be involved in the development and progression of many types of cancer.

In addition to its role in cancer, the DAC-like protein is also implicated in a wide range of other biological processes, including neurodegenerative diseases and developmental disorders. For example, the DAC-like protein has been shown to be involved in the regulation of neural development and in the treatment of Alzheimer's disease.

DAC-like protein targeting

DAC-like protein targeting is a promising approach to the development of new treatments for a wide range of diseases. By targeting the DAC-like protein, researchers can inhibit its function and potentially treat a wide range of diseases.

One of the key advantages of DAC-like protein targeting is its ability to target a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders. It is also a potent drug target, and has been shown to be involved in the development and progression of many types of cancer.

DAC-like protein inhibition

DAC-like protein inhibition is a promising approach to the development of new treatments for a wide range of diseases. By inhibiting the function of the DAC-like protein, researchers can potentially treat a wide range of diseases.

One of the key challenges in DAC-like protein inhibition is its ability to affect the function of multiple proteins. The DAC-like protein has been shown to interact with a wide range of transcription factors, including p53, and it is also involved in the regulation of

Protein Name: Dachshund Family Transcription Factor 1

Functions: Transcription factor that is involved in regulation of organogenesis. Seems to be a regulator of SIX1, SIX6 and probably SIX5. Corepression of precursor cell proliferation in myoblasts by SIX1 is switched to coactivation through recruitment of EYA3 to the SIX1-DACH1 complex. Transcriptional activation seems also to involve association of CREBBP. Seems to act as a corepressor of SIX6 in regulating proliferation by directly repressing cyclin-dependent kinase inhibitors, including the p27Kip1 promoter (By similarity). Inhibits TGF-beta signaling through interaction with SMAD4 and NCOR1. Binds to chromatin DNA via its DACHbox-N domain (By similarity)

The "DACH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DACH1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets